Physician profile
Tammy J Russo
NPI 1093976003
$568,226.74
in general payments reported to CMS, 2019-2025
22 companies · $253K in 2025
The $253K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $47K · 2023: $97K · 2024: $146K · 2025: $253K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $331K · Travel and Lodging: $111K · Food and Beverage: $24K · Consulting Fee: $15K · Honoraria: $15K · Education: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $330,631.00 |
| Travel and Lodging | $111,136.60 |
| Food and Beverage | $23,823.72 |
| Consulting Fee | $14,955.00 |
| Honoraria | $14,800.50 |
| Education | $461.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250,200.65 | 2021-2025 | Caplyta |
| Alkermes, INC. | $127,769.20 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $91,538.76 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $36,135.19 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $18,816.61 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $12,934.41 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $12,756.88 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $12,051.75 | 2024-2025 | Cobenfy |
| Allergan, INC. | $1,650.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $1,036.85 | 2022-2025 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $669.92 | 2021-2022 | |
| Corium, LLC | $589.06 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $552.15 | 2021-2023 | Nuedexta, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $463.54 | 2021-2025 | Trintellix |
| Lundbeck LLC | $257.14 | 2021-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $255.35 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $197.89 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $171.69 | 2021-2025 | Fanapt |
| Harmony Biosciences LLC | $120.99 | 2025 | |
| Avanir Pharmaceuticals, INC. | $28.78 | 2021-2022 | |
| Alfasigma USA, INC. | $15.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.